Journal of International Research in Medical and Pharmaceutical Sciences

Novel Drug Delivery Systems (NDDS) have emerged as pivotal technologies in modern therapeutics, addressing limitations of conventional drug administration such as poor bioavailability, non-specific targeting, and adverse side effects. The growing global market and rapid technological advancements underscore the need for a comprehensive understanding of NDDS development, market dynamics, and translational challenges.

This review systematically analyses recent progress in NDDS, focusing on key nanocarriers including liposomes, cubosomes, and solid lipid nanoparticles, alongside emerging multifunctional and stimuli-responsive systems. A thorough literature survey was conducted using databases such as PubMed, Scopus, and Web of Science, complemented by market reports and regulatory guidelines. Emphasis was placed on formulation techniques, material innovations, integration with personalised medicine, and the role of artificial intelligence in optimising design and clinical translation.

Results highlight significant advances in scalable manufacturing, green synthesis, and multifunctional hybrid platforms that enhance targeting and controlled release. However, challenges persist in regulatory approval, long-term safety evaluation, and market adoption, particularly due to complex manufacturing and intellectual property landscapes. The integration of digital health tools and real-time monitoring presents promising avenues to improve patient compliance and therapeutic outcomes.

In conclusion, NDDS represent a transformative shift toward precision medicine, but their successful clinical translation requires multidisciplinary collaboration, regulatory alignment, and sustainable manufacturing practices. Addressing current research gaps and leveraging emerging technologies will be critical to fully realise the therapeutic and commercial potential of NDDS, ultimately improving patient care worldwide.